Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Anacetrapib: Phase III ongoing

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Anacetrapib (MK-0859) Business: Cardiovascular Molecular target: Cholesteryl ester transfer protein (CETP) Description: Cholesteryl ester transfer protein (CETP) …

    Published on 11/23/2015
  • Apabetalone: Phase III started

    Resverlogix Corp. (TSX:RVX), Calgary, Alberta Product: Apabetalone (RVX000222) (RVX-208) Business: Cardiovascular Molecular target: Bromodomain containing 4 (BRD4); Apolipoprotein A-1 (APOA1) Description: Inhibitor of …

    Published on 11/23/2015
  • APD371: Phase Ib started

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Product: APD371 Business: Neurology Molecular target: Cannabinoid CB2 receptor (CNR2) Description: Cannabinoid CB2 receptor (CNR2) agonist Indication: Treat …

    Published on 11/23/2015
  • Autologous T cell therapy against CD19: Phase II started

    Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. Product: Autologous T cell therapy against CD19 (KTE-C19) Business: Cancer Molecular target: CD19 Description: Autologous T cells genetically modified to express a …

    Published on 11/23/2015
  • Avelumab: Phase III started

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Avelumab (MSB0010718C) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: …

    Published on 11/23/2015
  • D-Ivacaftor: Phase I started

    Concert Pharmaceuticals Inc. (NASDAQ:CNCE), Lexington, Mass. Product: D-Ivacaftor (CTP-656) (formerly C-10358) Business: Pulmonary Molecular target: Cystic fibrosis transmembrane conductance regulator (CFTR) Description…

    Published on 11/23/2015
  • DS003: Phase I started

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. International Partnership for Microbicides, Silver Spring, Md. Product: DS003 Business: Infectious Molecular target: HIV gp120 Description: Vaginal tablet formulation …

    Published on 11/23/2015
  • Elobixibat: Phase III started

    Albireo AB, Gothenburg, Sweden Ajinomoto Co. Inc. (Tokyo:2802), Tokyo, Japan Product: Elobixibat (A3309) Business: Gastrointestinal Molecular target: Solute carrier family 10 sodium-dependent bile acid transporter …

    Published on 11/23/2015
  • Encenicline: Extension study resumed

    Forum Pharmaceuticals Inc., Waltham, Mass. Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Encenicline (EVP-6124, MT-4666) Business: Neurology Molecular …

    Published on 11/23/2015
  • ENMD-2076: Phase II started

    CASI Pharmaceuticals Inc. (NASDAQ:CASI), Rockville, Md. Product: ENMD-2076 Business: Cancer Molecular target: Aurora kinase A (AURKA) (Aurora-A); Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1…

    Published on 11/23/2015
  • Faldaprevir: Phase IIa started

    Trek Therapeutics PBC, Cambridge, Mass. Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Faldaprevir (BI 201335) Business: Infectious Molecular target: HCV NS3/4A protease complex Description: Oral HCV NS3/4A …

    Published on 11/23/2015
  • GSK3174998: Phase I started

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: GSK3174998 Business: Cancer Molecular target: Tumor necrosis factor (TNF) receptor superfamily member 4 (TNFRSF4) (OX40) (CD134) Description: Humanized IgG1…

    Published on 11/23/2015
  • IW-1701: Phase Ia started

    Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), Cambridge, Mass. Product: IW-1701 Business: Cardiovascular Molecular target: Soluble guanylate cyclase (sGC) Description: Soluble guanylate cyclase (sGC) stimulator …

    Published on 11/23/2015
  • IW-1973: Phase Ib started

    Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), Cambridge, Mass. Product: IW-1973 Business: Cardiovascular Molecular target: Soluble guanylate cyclase (sGC) Description: Soluble guanylate cyclase (sGC) stimulator …

    Published on 11/23/2015
  • Kevetrin thioureidobutyronitrile: Completed Phase I enrollment

    Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Kevetrin thioureidobutyronitrile Business: Cancer Molecular target: Protein kinase B (AKT) (AKT1) (PKB) (PKBA); Leukotriene B4 (LTB4) Description: Small molecule …

    Published on 11/23/2015
  • NBI-640756: Phase I started

    Neurocrine Biosciences Inc. (NASDAQ:NBIX), San Diego, Calif. Product: NBI-640756 Business: Neurology Molecular target: NA Description: Undisclosed compound Indication: Treat essential tremor Endpoint: Safety and …

    Published on 11/23/2015
  • Otiprio: Phase IIIb started

    Otonomy Inc. (NASDAQ:OTIC), San Diego, Calif. Product: Otiprio (formerly AuriPro, OTO-201) Business: Infectious Molecular target: DNA gyrase Description: Sustained-release gel formulation of ciprofloxacin Indication: …

    Published on 11/23/2015
  • ReCell: Feasibility study started

    Avita Medical Ltd. (ASX:AVH; OTCQX:AVMXY), Perth, Australia Product: ReCell Business: Dermatology Molecular target: NA Description: Point-of-care autologous cell harvesting device that creates a regenerative epithelial …

    Published on 11/23/2015
  • Resolaris: Phase Ib/II started

    aTyr Pharma Inc. (NASDAQ:LIFE), San Diego, Calif. Product: Resolaris (ATYR1940) Business: Musculoskeletal Molecular target: NA Description: Protein therapy based on non-canonical functions of secreted forms of aminoacyl…

    Published on 11/23/2015
  • SM04690: Phase II started

    Samumed LLC, San Diego, Calif. Product: SM04690 Business: Autoimmune Molecular target: NA Description: Small molecule inhibitor of the Wnt pathway Indication: Treat moderate to severe osteoarthritis (OA) Endpoint: …

    Published on 11/23/2015
  • Subcutaneous rivipansel: Phase I started

    GlycoMimetics Inc. (NASDAQ:GLYC), Gaithersburg, Md. Halozyme Therapeutics Inc. (NASDAQ:HALO), San Diego, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Subcutaneous rivipansel Business: Hematology Molecular …

    Published on 11/23/2015
  • TD-6450: Phase IIa started

    Trek Therapeutics PBC, Cambridge, Mass. Theravance Biopharma Inc. (NASDAQ:TBPH), South San Francisco, Calif. Product: TD-6450 Business: Infectious Molecular target: HCV NS5A protein Description: Multivalent HCV NS5A …

    Published on 11/23/2015
  • TG1050: Phase I/ Ib started

    Transgene S.A. (Euronext:TNG), Illkirch, France Tasly Pharmaceutical Co. Ltd. (Shanghai:600535), Tianjin, China Product: TG1050 Business: Infectious Molecular target: NA Description: Adenovirus serotype 5 (Ad5) vector …

    Published on 11/23/2015
  • Vonapanitase: Completed Phase III enrollment

    Proteon Therapeutics Inc. (NASDAQ:PRTO), Waltham, Mass. Product: Vonapanitase (formerly PRT-201) Business: Renal Molecular target: Elastase Description: Recombinant human elastase Indication: Improve vascular access in …

    Published on 11/23/2015
  • Amikacin: Phase III ongoing

    Insmed Inc. (NASDAQ:INSM), Monmouth Junction, N.J. Product: Amikacin (Arikace, Arikayce)) (formerly SLIT amikacin) Business: Infectious Molecular target: Ribosomal 30S subunit Description: Inhaled liposomal amikacin …

    Published on 11/16/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993